{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:00:33Z","timestamp":1753876833608,"version":"3.41.2"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA049757"],"award-info":[{"award-number":["R01DA049757"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Understanding whether organizations with Medicare and Medicaid accountable care organization (ACO) contracts offer methadone provides important context about how organizations invested in payment and delivery system reform address the needs of patients with substance use disorders. We used data from the 2021-2022 National Survey of Accountable Care Organizations to assess whether organizations with ACO contracts, which are held accountable for the cost and quality of care for an assigned patient population, offered methadone to patients with opioid use disorder (OUD), and the organizational and contextual characteristics associated with doing so. We found that 28.3% of survey respondents reported that clinicians in their organizations offered methadone via an opioid treatment program. In adjusted analyses, organizations with a Medicaid ACO contract but no Medicare contract were more likely to offer methadone (46.0%, P &amp;lt; 0.05) than organizations with a Medicare-only contract (19.6%) or a Medicare and Medicaid contract (30.3%). Despite incentives to prioritize population health, most ACO-affiliated organizations were not offering individuals with OUD the full range of recommended medications and should work to enhance treatment options for this patient population.<\/jats:p>","DOI":"10.1093\/haschl\/qxaf074","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T07:40:23Z","timestamp":1744184423000},"source":"Crossref","is-referenced-by-count":0,"title":["Characteristics of accountable care organizations offering methadone to patients with opioid use disorder"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6816-5835","authenticated-orcid":false,"given":"Maia","family":"Crawford","sequence":"first","affiliation":[{"name":"The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth , Lebanon, NH 03756, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin A","family":"Barsky","sequence":"additional","affiliation":[{"name":"University of California College of the Law , San Francisco, CA 94102, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiden A","family":"Huskamp","sequence":"additional","affiliation":[{"name":"Department of Health Care Policy, Harvard Medical School , Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary F","family":"Brunette","sequence":"additional","affiliation":[{"name":"The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth , Lebanon, NH 03756, USA"},{"name":"Department of Psychiatry, Geisel School of Medicine \u00a0 at Dartmouth, Lebanon, NH 03756, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0211-1970","authenticated-orcid":false,"given":"Ellen","family":"Meara","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Harvard T.H. Chan School of Public Health , Boston, MA 02115 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"2025042306220791700_qxaf074-B1","doi-asserted-by":"publisher","first-page":"100052","DOI":"10.1016\/j.dadr.2022.100052","article-title":"What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size","volume":"3","author":"Keyes","year":"2022","journal-title":"Drug Alcohol Depend Rep."},{"issue":"8","key":"2025042306220791700_qxaf074-B2","doi-asserted-by":"publisher","first-page":"e2327488-e","DOI":"10.1001\/jamanetworkopen.2023.27488","article-title":"Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021","volume":"6","author":"Jones","year":"2023","journal-title":"JAMA Netw Open."},{"issue":"21","key":"2025042306220791700_qxaf074-B3","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/naloxone vs methadone for the treatment of opioid use disorder","volume":"332","author":"Nosyk","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"2025042306220791700_qxaf074-B4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1080\/10550887.2023.2165869","article-title":"Geographic variation in availability of opioid treatment programs across US communities","volume":"42","author":"Jehan","year":"2024","journal-title":"J Addict Dis."},{"key":"2025042306220791700_qxaf074-B5"},{"issue":"4","key":"2025042306220791700_qxaf074-B6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.18553\/jmcp.2017.16265","article-title":"The economic burden of opioid abuse: updated findings","volume":"23","author":"Kirson","year":"2017","journal-title":"J Manag Care Spec Pharm."},{"issue":"5","key":"2025042306220791700_qxaf074-B7","doi-asserted-by":"publisher","first-page":"339","DOI":"10.12788\/jhm.2736","article-title":"Planning and designing the improving addiction care team (IMPACT) for hospitalized adults with substance use disorder","volume":"12","author":"Englander","year":"2017","journal-title":"J Hosp Med."},{"issue":"1","key":"2025042306220791700_qxaf074-B8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/add.13555","article-title":"Effects of accountable care and payment reform on substance use disorder treatment: evidence from the initial 3 years of the alternative quality contract","volume":"112","author":"Stuart","year":"2017","journal-title":"Addiction"},{"issue":"4","key":"2025042306220791700_qxaf074-B9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/1475-6773.13625","article-title":"Impact of the medicare shared savings program on utilization of mental health and substance use services by eligibility and race\/ethnicity","volume":"56","author":"Acevedo","year":"2021","journal-title":"Health Serv Res."},{"key":"2025042306220791700_qxaf074-B10"},{"issue":"2","key":"2025042306220791700_qxaf074-B11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1176\/appi.ps.20230087","article-title":"Availability of medication for opioid use disorder among accountable care organizations: evidence from a national survey","volume":"75","author":"Newton","year":"2024","journal-title":"Psychiatric Services"},{"issue":"4","key":"2025042306220791700_qxaf074-B12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1215\/03616878-3150062","article-title":"Integration of substance abuse treatment organizations into accountable care organizations: results from a national survey","volume":"40","author":"D'Aunno","year":"2015","journal-title":"J Health Polit Policy Law."},{"issue":"4","key":"2025042306220791700_qxaf074-B13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/10775587231162681","article-title":"Internal and environmental predictors of physician practice use of screening and medications for opioid use disorders","volume":"80","author":"Miller-Rosales","year":"2023","journal-title":"Med Care Res Rev."},{"volume-title":"Availability of Medications for Opioid Use Disorder Under ACO Contracts 2017-2022 (NIDA R01DA049757)","year":"2022","author":"Crawford","key":"2025042306220791700_qxaf074-B14"},{"issue":"7","key":"2025042306220791700_qxaf074-B15","doi-asserted-by":"publisher","first-page":"e2323741-e","DOI":"10.1001\/jamanetworkopen.2023.23741","article-title":"Provision of digital health technologies for opioid use disorder treatment by US health care organizations","volume":"6","author":"Miller-Rosales","year":"2023","journal-title":"JAMA Netw Open."},{"issue":"1","key":"2025042306220791700_qxaf074-B16","doi-asserted-by":"publisher","first-page":"e2145691-e","DOI":"10.1001\/jamanetworkopen.2021.45691","article-title":"Factors associated with opioid overdose after an initial opioid prescription","volume":"5","author":"Weiner","year":"2022","journal-title":"JAMA Netw Open."},{"issue":"2","key":"2025042306220791700_qxaf074-B17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1377\/hlthaff.2019.00309","article-title":"Gaps in access to opioid use disorder treatment for medicare beneficiaries: an analysis of the availability of evidence-based, FDA-approved medication for opioid use disorder treatment for the nation's medicare population","volume":"39","author":"Harris","year":"2020","journal-title":"Health Aff."},{"key":"2025042306220791700_qxaf074-B18","doi-asserted-by":"publisher","first-page":"qxae076","DOI":"10.1093\/haschl\/qxae076","article-title":"Access to treatment before and after medicare coverage of opioid treatment programs","volume":"2","author":"Liu","year":"2024","journal-title":"Health Aff Sch."},{"key":"2025042306220791700_qxaf074-B19"},{"key":"2025042306220791700_qxaf074-B20"}],"container-title":["Health Affairs Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/advance-article-pdf\/doi\/10.1093\/haschl\/qxaf074\/62894185\/qxaf074.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/3\/4\/qxaf074\/62894185\/qxaf074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/3\/4\/qxaf074\/62894185\/qxaf074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T10:22:14Z","timestamp":1745403734000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article\/doi\/10.1093\/haschl\/qxaf074\/8108998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/haschl\/qxaf074","relation":{},"ISSN":["2976-5390"],"issn-type":[{"type":"electronic","value":"2976-5390"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,4,1]]},"article-number":"qxaf074"}}